The abstract is read at the publisher; the summary is JClub's.
Twenty-one antisense therapeutic oligonucleotides are approved, and a strong pipeline is positioned to expand clinical development in the coming years.
- Why it matters: The field needs a clear view of how antisense drugs work and what chemistry and delivery advances enabled recent clinical successes.
- What they did: This review summarizes mechanisms of action, key oligonucleotide chemistry and delivery advances, and provides a historical overview of approvals and major phase 3 studies.
- The result: The article frames future directions as broadening from rare diseases to common disorders, supported by the growing approval landscape and ongoing late-stage trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.